|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Inflammatory responses in hypoxic ischemic encephalopathy显示文摘 | Fudong Liu Louise D McCullough | 2013 | Acta Pharmacologica Sinica2013，34，9： | 45 |
| 2 | Non-invasive means of measuring hepatic fat content显示文摘Hepatic steatosis affects 20% to 30% of the general adult population in the western world. Currently, the technique of choice for determining hepatic fat deposition and the stage of fibrosis is liver biopsy. However, it is an invasive procedure and its use is limited, particularly in children. It may also be subject to sampling error. Non-invasive techniques such as ultrasound, computerised tomography (CT), magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy (1H MRS) can detect hepatic steatosis, but currently cannot distinguish between simple steatosis and steatohepatitis, or stage the degree of fibrosis accurately. Ultrasound is widely used to detect hepatic steatosis, but its sensitivity is reduced in the morbidly obese and also in those with small amounts of fatty infiltration. It has been used to grade hepatic fat content, but this is subjective. CT can detect hepatic steatosis, but exposes subjects to ionising radiation, thus limiting its use in longitudinal studies and in children. Recently, magnetic resonance (MR) techniques using chemical shift imaging have provided a quantitative assessment of the degree of hepatic fatty infiltration, which correlates well with liver biopsy results in the same patients. Similarly, in vivo 1H MRS is a fast, safe, non-invasive method forthe quantification of intrahepatocellular lipid (IHCL) levels. Both techniques will be useful tools in future longitudinal clinical studies, either in examining the natural history of conditions causing hepatic steatosis (e.g. non-alcoholic fatty liver disease), or in testing new treatments for these conditions. | Sanjeev R Mehta E Louise Thomas Jimmy D Bell Desmond G Johnston Simon D Taylor-Robinson | 2008 | World Journal of Gastroenterology2008，14，22： | 21 |
| 3 | Effect of nutritional counselling on hepatic,muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease显示文摘AIM: To assess the effectiveness of the current UK clinical practice in reducing hepatic fat (IHCL). METHODS: Whole body MRI and 1H MRS were obtained, before and after 6 mo nutritional counselling, from liver, soleus and tibialis muscles in 10 subjects with non-alcoholic fatty liver disease (NAFLD). RESULTS: A 500 Kcal-restricted diet resulted in an average weight loss of 4% (-3.4 kg,) accompanied by significant reductions in most adipose tissue (AT) depots, including subcutaneous (-9.9%), abdominal subcutaneous (-10.2%) and intra-abdominal-AT (-11.4%). Intramyocellular lipids (IMCL) were significantly reduced in the tibialis muscle (-28.2%). Decreases in both IHCL (-39.9%) and soleus IMCL (-12.2%) content were also observed, although these were not significant. Several individuals showed dramatic decreases in IHCL, while others paradoxically showed increases in IHCL content. Changes in body composition were accompanied by improvements in certain liver function tests: serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Significant correlations were found between decreases in IHCL and reductions in both intra-abdominal and abdominal subcutaneous AT. Improvements in liver function tests were associated with reductions in intra-abdominal AT, but not with changes in IHCL. CONCLUSION: This study shows that even a very modest reduction in body weight achieved through lifestyle modification can result in changes in body fat depots and improvements in LFTs. | E Louise Thomas Audrey E Brynes Gavin Hamilton Nayna Patel Adam Spong Robert D Goldin Gary Frost Jimmy D Bell Simon D Taylor-Robinson | 2006 | World Journal of Gastroenterology2006，12，36： | 13 |
| 4 | INT-767 improves histopathological features in a dietinduced ob/ob mouse model of biopsy-confirmed nonalcoholic steatohepatitis显示文摘AIM To characterize the efficacy of the dual FXR/TGR5 receptor agonist INT-767 upon histological endpoints in a rodent model of diet-induced and biopsy-confirmed non-alcoholic steatohepatitis(NASH).METHODS The effects of INT-767 on histological features of NASH were assessed in two studies using Lep^(ob/ob)(ob/ob) NASH mice fed the AMLN diet(high fat with transfat, cholesterol and fructose). In a proof-of-conceptstudy, Lep^(ob/ob)(ob/ob) NASH mice were first dosed with INT-767(3 or 10 mg/kg for 8 wk). A second ob/ob NASH study compared INT-767(3 and 10 mg/kg) to obeticholic acid(OCA)(10 or 30 mg/kg; 16 wk). Primary histological endpoints included qualitative and quantitative assessments of NASH. Other metabolic and plasma endpoints were also assessed. A comparative assessment of INT-767 and OCA effects on drug distribution and hepatic gene expression was performed in C57 Bl/6 mice on standard chow. C57 Bl/6 mice were orally dosed with INT-767 or OCA(1-30 mg/kg) for 2 wk, and expression levels of candidate genes were assessed by RNA sequencing and tissue drug levels were measured by liquid chromatography tandem-mass spectrometry.RESULTS INT-767 dose-dependently(3 and 10 mg/kg, PO, QD, 8 wk) improved qualitative morphometric scores on steatohepatitis severity, inflammatory infiltrates and fibrosis stage. Quantitative morphometric analyses revealed that INT-767 reduced parenchymal collagen area, collagen fiber density, inflammation(assessed by Galectin-3 immunohistochemistry) and hepatocyte lipid droplet area following INT-767 treatment. In a comparative study(16 wk), the FXR agonists OCA(10 and 30 mg/kg) and INT-767(3 and 10 mg/kg) both improved NASH histopathology, with INT-767 exerting greater therapeutic potency and efficacy than OCA. Mechanistic studies suggest that both drugs accumulate similarly within the liver and ileum, however, the effects of INT-767 may be driven by enhanced hepatic, but not ileal, FXR function. CONCLUSION These findings confirm the potential utility of FXR and dual FXR/TGR5 activation as disease intervention strategies in NASH. | Jonathan D Roth Michael Feigh Sanne S Veidal Louise KD Fensholdt Kristoffer T Rigbolt Henrik H Hansen Li C Chen Mathieu Petitjean Weslyn Friley Niels Vrang Jacob Jelsing Mark Young | 2018 | World Journal of Gastroenterology2018，24，2： | 7 |
| 5 | Comparative Effectiveness Research and Medical Informatics显示文摘 | Leonard W. D’Avolio Wildon R. Farwell Louis D. Fiore | 2010 | The American Journal of Medicine2010，，： | 4 |
| 6 | Evidence for the involvement of NOD2 in regulating colonic epithelial cell growth and survival显示文摘AIM: To investigate the function of NOD2 in colonic epithelial cells (CEC). METHODS: A combination of in vivo and in vitro analyses of epithelial cell turnover in the presence and absence of a functional NOD2 protein and, in response to enteric Salmonella typhimurium infection, were used. shRNA interference was also used to investigate the consequences of knocking down NOD2 gene expression on the growth and survival of colorectal carcinoma cell lines. RESULTS:In the colonic mucosa the highest levels of NOD2 expression were in proliferating crypt epithelial cells. Muramyl dipeptide (MDP), that is recognized by NOD2, promoted CEC growth in vitro . By contrast,the growth of NOD2-deficient CECs was impaired. In vivo CEC proliferation was also reduced and apoptosis increased in Nod2-/- mice, which were also evident following enteric Salmonella infection. Furthermore, neutralization of NOD2 mRNA expression in human colonic carcinoma cells by shRNA interference resulted in decreased survival due to increased levels of apoptosis. CONCLUSION: These findings are consistent with the involvement of NOD2 protein in promoting CEC growth and survival. Defects in proliferation by CECs in cases of CD may contribute to the underlying pathology of disrupted intestinal homeostasis and excessive inflammation. | Sheena M Cruickshank Louise Wakenshaw John Cardone Peter D Howdle Peter J Murray Simon R Carding | 2008 | World Journal of Gastroenterology2008，14，38： | 3 |
| 7 | Quality Improvement Guidelines for the Treatment of Lower Extremity Deep Vein Thrombosis with Use of Endovascular Thrombus Removal显示文摘 | Suresh Vedantham Patricia E. Thorpe John F. Cardella Clement J. Grassi Nilesh H. Patel Hector Ferral Lawrence V. Hofmann Bertrand M. Janne d’Othée Vittorio P. Antonaci Elias N. Brountzos Daniel B. Brown Louis G. Martin Alan H. Matsumoto Steven G. Meranze | 2006 | Journal of Vascular and Interventional Radiology2006，，3： | 3 |
| 8 | Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial显示文摘 | John Primrose Stephen Falk Meg Finch-Jones Juan Valle Derek O’Reilly Ajith Siriwardena Joanne Hornbuckle Mark Peterson Myrddin Rees Tim Iveson Tamas Hickish Rachel Butler Louise Stanton Elizabeth Dixon Louisa Little Megan Bowers Sian Pugh O James Garden D | 2014 | Lancet Oncology2014，，6： | 2 |
| 9 | Evaluation of microdiets versus live feeds on growth, survival and fatty acid composition of larval haddock ( Melanogrammus aeglefinus )显示文摘 | Tammy Blair John Castell Steven Neil Louis D’Abramo Chantal Cahu Paul Harmon Kehinde Ogunmoye | 2003 | Aquaculture2003，，1： | 2 |
| 10 | Myosin binding protein C:Structural abnormalities in familial hypertrophic cardiomyopathy显示文摘The muscle protein myosin binding protein C (MyBPC) is a large multi-domain protein whose role in the sarcomere is complex and not yet fully understood. Mutations in MyBPC are strongly associated with the heart disease familial hypertrophic cardiomyopathy (FHC) and these experiments of nature have provided some insight into the intricate workings of this protein in the heart. While some regions of the MyBPC molecule have been assigned a function in the regulation of muscle contraction, the interaction of other regions with various parts of the myosin molecule and the sarcomeric proteins, actin and titin, remain obscure. In additic n, several intra-domain interactions between adjacent MyBPC molecules have been identified. Although the basic structure of the molecule (a series of immunoglobulin and fibronectin domains) has been elucidated, the assembly of MyBPC in the sarcomere is a topic for debate. By analysing the MyBPC sequence with respect to FHC-causing mutations it is possible to identify individual residues or regions of each domain that may be important either for binding or regulation. This review looks at the current literature, in concert with alignments and the structural models of MyBPC, in an attempt to understand how FHC mutations may lead to the disease state. | Cecily E OAKLEY Brett D HAMBLY Paul MG CURMI Louise J BROWN | 2004 | Cell Research2004，14，2： | 2 |
| 11 | Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease显示文摘 | Benjamin Pariente Guillaume Pineton de Chambrun Roman Krzysiek Marine Desroches Gauthier Louis Chiara De Cassan Clotilde Baudry Jean‐Marc Gornet Pierre Desreumaux Dominique Emilie Jean‐Frédéric Colombel Matthieu Allez | 2011 | Inflamm Bowel Dis2011，，7： | 2 |
| 12 | Evidence That the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor Gene in db / db Mice显示文摘 | Hong Chen Olga Charlat Louis A Tartaglia Elizabeth A Woolf Xun Weng Stephen J Ellis Nathan D Lakey Janice Culpepper Karen J More Roger E Breitbart Geoffrey M Duyk Robert I Tepper Jay P Morgenstern | 1996 | Cell1996，，3： | 2 |
| 13 | Natural History of Pediatric Crohn’s Disease: A Population-Based Cohort Study显示文摘 | Gwenola Vernier–Massouille Mamadou Balde Julia Salleron Dominique Turck Jean Louis Dupas Olivier Mouterde Véronique Merle Jean Louis Salomez Julien Branche Raymond Marti éric Lerebours Antoine Cortot Corinne Gower–Rousseau Jean Frédéric Colombel | 2008 | Gastroenterology2008，，4： | 2 |
| 14 | Neuroendocrine pharmacology of stress显示文摘 | Gonzalo A Carrasco Louis D Van de Kar | 2003 | European Journal of Pharmacology2003，，1： | 1 |
| 15 | Tumor necrosis factor gene polymorphism influences TNF alpha produc-tion in LPS-stimulated whole blood cell culture in healthy humans显示文摘 | Louis E Franchimont D Piron A | | 0，，3： | 1 |
| 16 | Influence treatment efficacy in childhood acute lymphoblastic leukemia显示文摘 | Marie Louise D Kim D Kjeld S | 2008 | Pediatr Hematol Oncol2008，30，11： | 1 |
| 17 | Quality Improvement Guidelines for the Treatment of Lower Extremity Deep Vein Thrombosis with Use of Endovascular Thrombus Removal显示文摘 | Suresh Vedantham Patricia E. Thorpe John F. Cardella Clement J. Grassi Nilesh H. Patel Hector Ferral Lawrence V. Hofmann Bertrand M. Janne d’Othée Vittorio P. Antonaci Elias N. Brountzos Daniel B. Brown Louis G. Martin Alan H. Matsumoto Steven G. Meranze | 2009 | Journal of Vascular and Interventional Radiology2009，，7： | 1 |
| 18 | Increasing incidence of thyroid cancer in the United States, 1973-2002显示文摘 | Louise D H Gilbert W | 2006 | Jama the Journal of the American Medical Association2006，295，18： | 1 |
| 19 | Optimising monitoring in the management of Crohn’s disease: A physician’s perspective显示文摘 | Pavol Papay Ana Ignjatovic Konstantinos Karmiris Heda Amarante Pal Milheller Brian Feagan Geert D’Haens Philippe Marteau Walter Reinisch Andreas Sturm Flavio Steinwurz Laurence Egan Julián Panés Edouard Louis Jean-Frédéric Colombel Remo Panaccione | 2013 | Journal of Crohn’s and Colitis2013，，： | 1 |
| 20 | The Ten-year Single-center Experience With 6-Mercaptopurine in the Treatment of Inflammatory Bowel Disease显示文摘 | Kenneth D Glazier Adam L Palance Louis H Griffel Kiron M Das | 2005 | Journal of Clinical Gastroenterology2005，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员